BrightPath Biotherapeutics (4594) Stock Overview

BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. It is developing GRN-1201, a cancer peptide vaccine candidate that is in Phase II clinical trials for the treatment of non-small cell lung cancer, as well as in Phase I clinical trials to treat melanoma. The company is also developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers. In addition, its product candidates in preclinical trials include BP1202 that targets CD39; BP1210, which suppresses T cell cytotoxicity; BP1212 to inhibit TIM-3 and CD39; BP1209 to target tumor-specific neoantigens; and BP1200 to target CD73. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was incorporated in 2003 and is headquartered in Tokyo, Japan.

4594 Stock Information

Symbol

4594

Address

Kojimachi Central BuildingTokyo, Japan

Founded

Trading hours

Website

https://www.brightpathbio.com

Country

🇯🇵 Japan

Phone Number

BrightPath Biotherapeutics (4594) Price Chart

BrightPath Biotherapeutics Overview: Key Details and Summary

Stock data	2023	Change
Price	$0.41673898824525174	N/A
Market Cap	$24.86M	N/A
Shares Outstanding	59.66M	14.75%
Employees	42.00	N/A
Shareholder Equity	1.57B	-38.08%

Valuation	2023	Change
P/E Ratio	-0.02	N/A
P/S Ratio	677.96	N/A
P/B Ratio	0.02	N/A

Growth	2023	Change
Return on Equity	-0.0066	N/A

Earnings	2023	Change
Revenue	$36.67K	N/A
Earnings	-$10.32M	N/A
EPS	-24.90	N/A
Earnings Yield	-59.75	N/A
Gross Margin	0.6409	N/A
Operating Margin	-277.85	N/A
Net income margin	-281.37	N/A

Financial Strength	2023	Change
Total Assets	$11.82M	N/A
Cash on Hand	$10.63M	N/A
Debt to Equity	0.0006	-9.79%
Current Ratio	$21.57	47.72%